Abstract: A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided.

Abstract: A method is provided for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid or ester thereof. The method involves the hydrolyzing an ortho ester of a water-soluble polymer so as provide the corresponding acid. In addition, the invention provides water-soluble polymers bearing a terminal carboxylic acid or ester thereof, intermediates and reagents useful in carrying out the method, as well as gels, pharmaceutical formulations, conjugates related to the described water-soluble polymer derivatives.

Abstract: A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided.

Abstract: The present specification generally relates to compositions comprising a thermoresponsive polymer and methods of treating a soft tissue condition using such compositions.

Abstract: The present invention provides compositions which not only effectively kill a broad spectrum of microorganisms present on surfaces on contact but continue to kill microorganisms for a period of time thereafter.

Abstract: A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, and an implantable device coated with the composition are provided.

Abstract: A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided.

Abstract: The present disclosure is directed, in part, to a curable composition, a method for augmenting a structure in a patient with a resorbable biocompatible polymer, and a biodegradable, resorbable implant comprising a biocompatible copolymer. An exemplary embodiment of the curable composition comprises (a) 60 wt. % to 95 wt. % of one or more vinyl ester monomers and/or vinylcarbonate monomers, wherein said one or more vinyl ester monomers and/or vinylcarbonate monomers are respectively selected from compounds of the general formulas (I) and (II) below: wherein n, m R1 and R2 have the meaning defined herein; (b) 0.1 to 40 wt. % of one or more multifunctional thiols; and (c) 0 to 10 wt. % of a biocompatible polymerization initiator.

Abstract: The invention provides hydrogels and methods for their use in treating disorders of the retina such as age-related macular degeneration (AMD).

Abstract: Provided is a formulation for oral teeth, which includes a plurality of calcium ion carriers and a plurality of calcium-containing particulates. The particulates are carried by the calcium ion carriers, such that the formulation can prevent or rapidly treat dentin-associated symptoms or diseases, while providing a prolonged prophylactic or therapeutic effect.

Abstract: A novel process of manufacturing sevelamer carbonate from a polyallylamine carbonate or bicarbonate chloride salt. Process for manufacture of carbonate and/or bicarbonate salts of water insoluble polymers containing amino groups that are useful as anion binders in the gastrointestinal (GI) system. The process arranges the polyallylamine chain in a solution in such a way that the cross-linking reaction with epichlorohydrin can be controlled at a desired reaction rate.

Abstract: Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, therapeutic agent delivery systems that include the cationic polymers, methods for administering a therapeutic agent using the delivery systems, and methods for making and using the cationic polymers, monomers, surfaces, and therapeutic agent delivery systems.

Abstract: A fibrous tissue scaffold wherein fibres of the scaffold comprise a phosphonic acid polymer. The fibres preferably incorporate a vinylphosphonic acid—acrylic acid copolymer, and may further include polycaprolactone. There is further described medical implant coating comprising a phosphonic acid polymer, a biocompatible fibre comprising a phosphonic acid polymer and a biocompatible polymer comprising polycaprolactone and a phosphonic acid polymer.

Abstract: Provided is an electroactive structure and method for growing isolated differentiable cells comprising a three dimensional matrix of fibers formed of a biocompatible synthetic piezoelectric polymeric material, wherein the matrix of fibers is seeded with the isolated differentiable cells and forms a supporting scaffold for growing the isolated differentiable cells, and wherein the matrix of fibers stimulates differentiation of the isolated differentiable cells into a mature cell phenotype on the structure.

Abstract: The invention provides a therapeutic composition comprising an aqueous buffer, and a therapeutic agent that improves the functioning of a diseased heart by decreasing left ventricular end-diastolic pressure and simultaneously increasing left ventricular ejection without affecting the blood pressure or heart rate.

Abstract: Functional gel particle formed from a crosslinked polymeric network including a fraction of stable crosslinks and a second fraction of cleavable crosslinks are disclosed. Functional compounds may be chemically or physically encapsulated within and/or released from the gel particle by selective cleavage of the cleavable crosslinks. The functional compounds may be delivered and released to a pre-selected target site. Peripheral or other accessible functionality on the surface of the gel particle allows attachment of a surface reactive agent, thereby modifying one or more surface properties of the gel particle. Processes of preparing the gel particles and processes of delivering the functional compounds to a target site are also disclosed.

Abstract: One aspect of the invention relates to a hydrogel comprising a polymer comprising a plurality of pendent hydroxyl groups, a crosslinker, and a sclerosing agent. Another aspect of the invention relates to a method for reducing lung volume in a patient comprising the steps of advancing into a region of a patient's lung via said patient's trachea a multi-lumen catheter lumen through a bronchoscope; and co-administering, through the multi-lumen catheter, a first mixture comprising a first amount of a polymer containing a plurality of pendent hydroxyl groups; a second mixture comprising a second amount of a crosslinker; and a third mixture comprising a third amount of a sclerosing agent; thereby forming a hydrogel in said region. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema of the lung.

Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: The present invention provides a method of manufacturing a hydrogel comprising the step of crosslinking a biopolymer using a carbodiimide crosslinker of Formula I wherein at least one of R1 and R2 is a functional group that is a bulky organic functional group. R1 and R2 can each independently be an optionally substituted saturated or unsaturated functional group selected from the group consisting of an alkyl, a cycloalkyl, a heterocyclic, and an aryl. The bulky organic functional group will slow down the crosslinking reaction of carbodiimide due to the steric effects and/or electronic effects, in comparison to a crosslinking reaction using EDC. Also provided are the hydrogels and ophthalmic devices prepared using the method of the invention and uses thereof.

Abstract: According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable.

Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.

Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.

Abstract: A solid material adapted to kill bacteria in planktonic, spore and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The solid material includes a significant amount of one or more surfactants entrained in a crosslinked polymeric network.

Abstract: An aqueous emulsion comprising at least a covalently bound vinyl oligomer and vinyl polymer, wherein said vinyl oligomer comprises 5 to 85 mol % of vinyl monomers bearing quaternary ammonium ion functional groups or quaternisable amine functional groups and is obtained by a controlled radical polymerisation of at least one vinyl monomer via a reversible addition-fragmentation chain transfer mechanism in solution in the presence of a control agent and a source of free radicals; wherein said vinyl polymer is obtained by emulsion polymerisation of vinyl monomers in the presence of the vinyl oligomer; wherein the weight % ratio of vinyl oligomer to vinyl polymer is in the range of from 0.5:99.5 to 65:35.

Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.

Abstract: A tissue thickness compensator may generally comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a third layer comprising a third medicament. The tissue thickness compensator may comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a reservoir comprising a third medicament disposed within the reservoir. The medicaments may be independently selected from a haemostatic agent, an anti-inflammatory agent, an antibiotic agent, anti-microbial agent, an anti-adhesion agent, an anti-coagulant agent, a pharmaceutically active agent, a matrix metalloproteinase inhibitor, and combinations thereof. Articles of manufacture comprising the tissue thickness compensator and methods of making and using the tissue thickness compensator are also described.

Abstract: This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use.

Abstract: Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, therapeutic agent delivery systems that include the cationic polymers, methods for administering a therapeutic agent using the delivery systems, and methods for making and using the cationic polymers, monomers, surfaces, and therapeutic agent delivery systems.

Abstract: The invention relates to therapeutic methods comprising use of oligomeric and polymeric forms of the monoterpene compounds alloocimene, limonene, alpha-pinene, beta-pinene, geranyl acetate, alpha-phellandrene, gamma-terpinene, 3-carene and 2-carene. More particularly, the invention relates to methods of treating degenerative neurological conditions, and treating skin disorders.

Abstract: A podiatric filler composition comprising a pliable biocompatible material and a physiologically acceptable suspending agent. The podiatric filler compositions may be used in methods for treating fat pad atrophy, foot pain, plantar faciitis, metatarsalgia, injury, and rheumatoid arthritis.

Abstract: The present invention provides bioactive bone cements that not only have sufficient radiopacity, low physiological toxicity, and requisite mechanism strength, but also promote local bone in-growth. The bone cement utilizes strontium salts as radiopacifiers, and comprises a powder component and a liquid component. In an embodiment, the powder component comprises a strontium salt, poly(methyl methacrylate) (PMMA), and a polymerization initiator; and the liquid component comprises methyl methacrylate (MMA) as reactive monomers and a polymerization accelerator.

Abstract: The present invention relates to a bio-stable hydrogel for use in the treatment and prevention of incontinence and vesicouretal reflux. The hydrogel is obtainable by combining acrylamide and methylene bis-acrylamide in amounts to provide about 0.5 to 25% by weight polyacrylamide, based on the total weight of the hydrogel.

Abstract: Liquid hemostatic coating materials comprise a cyanoacrylate monomer and a solvent system comprising a volatile, non-reactive liquid that is non-stinging and non-irritating to a user. The material forms a coating or bandage in the form of a film that when applied and adhered to a surface or to the skin of a user inhibits the application surface from adhering to another surface.

Abstract: The application discloses a process for making a polymer having pendant side groups comprising: (i) polymerising an olefinically unsaturated monomer functionalized with (a) an azide group optionally protected by a protecting group, or (b) an alkyne group optionally protected by a protecting group, by living radical polymerization, most preferably RAFT, transitional metal mediated living radical polymerization (TMM-LRP) and/or atom transfer radical polymerization, to produce a polymer intermediate; (ii) removing, when present, at least a portion of the total number of protecting groups from the polymer intermediate; (iii) reacting the polymer intermediate with at least one pendant side group moiety functionalised with (a) an alkyne group or (b) an azide group respectively so that the alkyne and azide groups react to attach the pendant side group to the polymer. Processes for making supports comprising pendant side groups, and polymers and supports prepared by the method are also disclosed.

Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.

Abstract: Novel methods and compositions of nanocomposites are provided. One exemplary composition comprises a biocompatible polymer, such as polypropylene fumarate, and a carbon nanotube, such as a single walled carbon nanotube, an ultra-short carbon nanotube, or a substituted ultra-short carbon nanotube. An exemplary method comprises providing a biocompatible polymer and a carbon nanotube and combining a biocompatible polymer and a carbon nanotube to form a nanocomposite. Another exemplary method comprises providing a nanocomposite comprising a biocompatible polymer and a carbon nanotube and administering the composition to a subject.

Abstract: The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.

Abstract: A method is provided for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid or ester thereof. The method involves the hydrolyzing an ortho ester of a water-soluble polymer so as provide the corresponding acid. In addition, the invention provides water-soluble polymers bearing a terminal carboxylic acid or ester thereof, intermediates and reagents useful in carrying out the method, as well as gels, pharmaceutical formulations, conjugates related to the described water-soluble polymer derivatives.

Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to. a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.

Abstract: The invention relates to novel ethylene copolymers comprising 10-60% polyethylenglycol (meth)acrylate monomers and 40-90% substantially cationic monomer. Compositions, in particular cosmetic or pharmaceutical compositions, containing the inventive copolymers and a cosmetic treatment method using said copolymers are also disclosed.

Abstract: A polymer having a number average molecular weight (Mn) of about 10 000 g/mol comprising a monomeric rigid moiety R and a monomeric flexible moiety F, wherein R comprises a main-chain polycyclic core and F has a main chain comprising a number of atoms sufficient for the transition temperature of the polymer to be lower than the degradation temperature of the polymer is provided. A method of manufacturing of same is also provided. Biomedical devices, scaffolds and supports for tissue engineering, delivery devices, textiles, moulds, vehicle parts, tubes, active disassembly devices, microactuators, toys and inflatable membranes comprising same are also described.

Abstract: The present invention provides a non-human animal model of myocardial infarction, which can be created by a less invasive method, shows an extremely low mortality during and after surgical induction of myocardial infarction, ensures the blood reflow after necrosis of cardiac muscles caused by blocking blood flow, and therefore, is usable in topical therapy for myocardial infarction and studies on regenerative medicine. The present invention also provides a method for creating the non-human animal model comprising administering a temporary embolic agent to a branch blood vessel of a heart coronary artery to block blood flow in the branch blood vessel; and after a definite period of time after said vascular branch blockage, administering a temporary embolic agent to the target coronary artery which is intended to induce myocardial infarction to block blood flow in the target coronary artery.

Abstract: A transparent lacquer composition that can be used as a protective and gloss lacquer for surface coating is described. The lacquer composition can be a dental material and a method for preparing a lacquer composition is also described. Also described are novel polymerizable monomers comprising at least one polyalicyclic structure element and certain ethylenic structure elements that are particularly suitable for use in a lacquer composition.

Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with microparticles, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.

Abstract: The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided.

Abstract: A sheet for pest control, wherein said sheet is of polymeric material and comprises at least two layers; a top layer and a bottom layer, wherein the bottom layer contains a herbicide and one or more pesticides selected from among fungicides and insecticides, and the top layer optionally containing an insecticide and/or fungicide. Other aspects of the invention include a polymeric composition used in the preparation of the sheets and a method for pest control in agriculture, horticulture and gardens.

Abstract: Biocompatible and resorbable melt derived glass compositions which include: SiO2 60-70 weight-%, Na2O 5-20 weight-%, CaO 5-25 weight-%, MgO 0-10 weight-%, P2O5 0.5-3.0 weight-%, B2O3 0-15 weight-%, Al2O3 0-5 weight-%, and which contain less than 0.05 weight-% potassium. Biocompatible and resorbable glass fibres manufactured from these glass compositions, medical devices containing fibres of the invention, the use of these compositions for the manufacture of glass fibre and the use of the fibres for the manufacture of medical devices are also disclosed.

Abstract: The disclosure relates to polymer films containing iodinated resin, where such films have advantageous antibacterial and/or antitoxic properties. The films may be used, for example, in medical tape, wound dressings and bandages. In certain embodiments, the invention is also directed to methods of manufacturing such polymer films, where various manufacturing difficulties have been addressed and overcome.

Abstract: A composition for stimulating NKT cells to produce anti-cancer and anti-viral cytokines without causing anergy of NKT cells includes a glycolipid antigen and a nanoparticle conjugated with the glycolipid antigen. The glycolipid antigen and the nanoparticle are not antigenic in mouse and human being. The composition can further include covalent or non-covalent connection between the glycolipid antigen and the nanoparticle. The glycolipid antigen is alpha-galactosylceramide or an analog of that. The nanoparticle can be a polymer. A production method of the composition includes preparing a nanoparticle and a glycolipid antigen and loading the glycolipid antigen to the nanoparticle. The glycolipid antigen can be coated onto the surface of the nanoparticle or encapsulated within the nanoparticle. A method of stimulating NKT cells to produce anti-cancer and anti-viral cytokines without causing anergy of NKT cells is also provided.

Abstract: Curcumin, a polyphenol extracted from the rhizome turmeric, has been polymerized to produce a polymer material having a backbone of one or more repeating structural units, at least one of which comprises a curcumin monomer residue. These curcumin-containing polymers have a wide range of pharmacological activities, including, among others antitumor, antioxidant, antiinflammatory, antithrombotic and antibacterial activities. Certain species of these polymers have exhibited remarkable antitumor activity. Water-soluble curcumin derivatives and their use as prodrugs and prodrug carriers are also disclosed.